Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)


Creative Commons License

Drake M. J., Chapple C., Esen A. A., Athanasiou S., Cambronero J., Mitcheson D., ...Daha Fazla

EUROPEAN UROLOGY, cilt.70, sa.1, ss.136-145, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 70 Sayı: 1
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1016/j.eururo.2016.02.030
  • Dergi Adı: EUROPEAN UROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.136-145
  • Anahtar Kelimeler: Add-on therapy, Incontinence, Mirabegron, Overactive bladder, Solifenacin, QUALITY-OF-LIFE, URINARY-INCONTINENCE, NERVE-STIMULATION, IMPACT, ONABOTULINUMTOXINA, PERCEPTION, AGONIST, BURDEN
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Background: Incontinence has a greater detrimental effect on quality of life than other symptoms of overactive bladder (OAB) and is often difficult to treat with antimuscarinic monotherapy.